obesity

Roche obesity drug drives 15.5% weight loss in diabetes trial

Roche announced on Tuesday that its experimental obesity drug enicepatide helped patients with type 2 diabetes achieve an average 15.5% body weight reduction and restored many to non-diabetic blood sugar levels in a mid-stage clinical trial, bolstering the Swiss drugmaker's…

Novo’s CagriSema tops Eli Lilly’s tirzepatide in new trial

Novo unveiled new clinical data on Monday showing its experimental obesity drug CagriSema delivered superior weight loss compared to a lower dose of Eli Lilly's tirzepatide, offering a rebound for the company after its next-generation treatment stumbled in a head-to-head…

Novo Nordisk says Wegovy helped 2 in 5 young children beat obesity in trial

Novo Nordisk on Monday announced that its blockbuster weight-loss drug semaglutide, marketed as Wegovy, helped two in five young children move below the obesity threshold in a landmark clinical trial — the first to test the GLP-1 medication in children…

Novo Nordisk launches Wegovy pill in Germany, its first EU market

As Novo Nordisk expands the global footprint of its blockbuster weight-loss drug Wegovy, the cardiovascular benefits first demonstrated in the SELECT trial remain central to the medication's growing dominance and widening insurance coverage.

Novo Nordisk begins Phase I trial for secret obesity drug

Novo Nordisk has quietly registered a first-in-human Phase I clinical trial for a previously undisclosed obesity candidate, NNC0721-8060, marking the first public emergence of the experimental program. The company has revealed no details about the drug's molecular target, mechanism of…

Cambridge study solves weight loss drug paradox

Scientists at the University of Cambridge have resolved a longstanding puzzle in obesity pharmacology: why both activating and blocking the same receptor can lead to weight loss. The answer, published July 24 in Nature Metabolism, lies in two anatomically separate…

Lilly plans Q1 2027 FDA filing for obesity drug retatrutide

Eli Lilly announced Thursday that it will submit a Biologics License Application for its next-generation obesity drug retatrutide to the U.S. Food and Drug Administration in the first quarter of 2027, after reporting positive results from two additional Phase 3…

EU approves Wegovy pill as first oral weight-loss drug

Novo Nordisk announced Wednesday that the European Commission has approved its once-daily oral Wegovy pill for weight management in adults with obesity, making it the first GLP-1 receptor agonist available in tablet form across all 27 EU member states.

High-fat diet and gut bacteria boost cancer immunotherapy, study finds

A new study published in Nature on July 8 reveals a counterintuitive finding: a high-fat diet that promotes obesity can, when paired with the right gut bacteria, enhance the effectiveness of cancer immunotherapy. The research demonstrates that the bacterium Lactobacillus…

Wegovy is only obesity drug linked to reduced death risk, BMJ analysis finds

A comprehensive analysis published in The BMJ on July 8 found that subcutaneous semaglutide — marketed as Wegovy — is the only obesity drug associated with reduced risks of death, heart attack, and heart failure, reinforcing Novo Nordisk's position in…

Eli Lilly says Trump pricing policy will delay obesity drug launches in Europe

Eli Lilly said on Tuesday that the Trump administration's most-favored-nation pricing policy will affect its plans to launch its weight-loss pill in Europe and Britain, with the rollout now expected in the second half of 2026 or early 2027. The…

AstraZeneca obesity pill moves to Phase III after nearly 12% weight loss in mid-stage trials

AstraZeneca unveiled full results from two mid-stage trials of its experimental oral obesity drug elecoglipron on Monday at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, revealing that the once-daily pill produced an average body weight reduction of…